COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF MULTIPLE MYELOMA

被引：0
|
作者：
Maclachlan, K. [1 ,2 ]
Cuddihy, A. [1 ]
Hein, N. [3 ]
Harrison, S. [2 ]
Hannan, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Peter MacCallum Canc Ctr, Res Div, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Australian Natl Univ, Dept Canc Biol & Therapeut, Canberra, ACT, Australia
[4] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[7] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1240
引用
收藏
页码：512 / 512
页数：1
相关论文
共 50 条
  • [41] In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059-As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma
    Savvidou, Ioanna
    Khong, Tiffany T.
    Horrigan, Stephen K.
    Spencer, Andrew
    BLOOD, 2015, 126 (23)
  • [42] Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma
    Cirstea, Diana
    Hideshima, Teru
    Santo, Loredana
    Eda, Homare
    Scullen, Tyler A.
    Nemani, Neeharika
    Mahindra, Anuj
    Yee, Andrew
    Hu, Yiguo
    Mimura, Naoya
    Minami, Jiro
    Ohguchi, Hiroto
    Suzuki, Rikio
    Cottini, Francesca
    Guichard, Sylvie M.
    Anderson, Kenneth C.
    Raje, Noopur
    BLOOD, 2012, 120 (21)
  • [43] Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Alegria, Victoria R.
    Ahmed, Salman
    Laplant, Betsy
    Manna, Alak
    Parrondo, Ricardo
    Roy, Vivek
    Sher, Taimur
    Edwards, Brett
    Lanier, Stephanie
    Jackson, Keisha
    Chanan-Khan, Asher A.
    Paulus, Aneel
    BLOOD, 2019, 134
  • [44] Combination drug screen identifies novel epigenetic therapies to enhance menin inhibitor efficacy in KMT2A rearranged and NPM1 mutant AML
    Totiger, Tulasigeri M.
    Chaudhry, Sana
    Montoya, Skye
    Affer, Maurizio
    Sondhi, Anya K.
    Chirino, Alexandra
    Volmar, Claude-Henry
    Brothers, Shaun
    Watts, Justin
    Taylor, Justin
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Gene expression and proteomic profiling of drug-treated multiple myeloma (MM) cells: Mechanisms of drug-responsiveness vs. resistance and rationale for design of novel combination therapies for MM.
    Mitsiades, CS
    Mitsiades, N
    Bailey, C
    Gu, XS
    Joseph, M
    Fanourakis, G
    Munshi, NC
    Poulaki, V
    Liberman, TA
    Anderson, KC
    BLOOD, 2002, 100 (11) : 389A - 389A
  • [46] Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
    Driessen, Christoph
    Kraus, Marianne
    Joerger, Markus
    Rosing, Hilde
    Bader, Jurgen
    Hitz, Felicitas
    Berset, Catherine
    Xyrafas, Alexandros
    Hawle, Hanne
    Berthod, Gregoire
    Overkleeft, Hermann S.
    Sessa, Christiana
    Huitema, Alwin
    Pabst, Thomas
    von Moos, Roger
    Hess, Dagmar
    Mey, Ulrich J. M.
    HAEMATOLOGICA, 2016, 101 (03) : 346 - 355
  • [47] An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma
    Raje, Noopur
    Richardson, Paul
    Hari, Parameswaran N.
    Mahindra, Anuj
    Kaster, Sarah
    Connolly, Christine
    Rivera, Linda
    Chetri, Gaurav
    Dean, Sarah
    Jacobs, Paulette
    Saad, Ayman
    Laubach, Jacob
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Adams, Jennifer
    Makrides, Wendy
    Weller, Edie
    Munshi, Nikhil
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1483 - 1483
  • [48] A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) in patients with relapsed or refractory multiple myeloma
    Berenson, JR
    BLOOD, 2004, 104 (11) : 659A - 659A
  • [49] AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
    Santo, L.
    Vallet, S.
    Hideshima, T.
    Cirstea, D.
    Ikeda, H.
    Pozzi, S.
    Patel, K.
    Okawa, Y.
    Gorgun, G.
    Perrone, G.
    Calabrese, E.
    Yule, M.
    Squires, M.
    Ladetto, M.
    Boccadoro, M.
    Richardson, P. G.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N.
    ONCOGENE, 2010, 29 (16) : 2325 - 2336
  • [50] AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
    L Santo
    S Vallet
    T Hideshima
    D Cirstea
    H Ikeda
    S Pozzi
    K Patel
    Y Okawa
    G Gorgun
    G Perrone
    E Calabrese
    M Yule
    M Squires
    M Ladetto
    M Boccadoro
    P G Richardson
    N C Munshi
    K C Anderson
    N Raje
    Oncogene, 2010, 29 : 2325 - 2336
12345